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Purpose/Objective: To assess the impact of our experience 
with permanent prostate brachytherapy (PBB) along 8 years. 
Materials and Methods: From September 2004 to July 2012, 
247 patients with prostate cancer diagnosis were treated 
with low-dose brachytherapy by real-time planning, 125-I 
loose seeds (SelectSeed model, Isotron lab., Germany), Spot 
Pro planning system (Nucletron/Elekta, Stockholm, Sweden) 
and automatic delivery system (SeedSelectron, 
Nucletron/Elekta, Stockholm, Sweden). Patients were 
chronologically divided into 5 groups: P1 (n=50), P2 (n=50), 
P3 (n=50), P4 (n=50), P5 (n=47). The parameters reported 
were: D90 (dose received by 90% of the prostate volume), 
V100 (prostate volume receiving 100% of the prescribed 
dose), V150, V200, UV150 (for urethra), RV100 (for rectum), 
conformational number (CN), dose homogeneity index (DHI), 
number of needles and seeds and nomogram data. No post-
implant parameters were reported in this study. To analyze 
the procedure treatments time, we rejected 27 cases, in 
which the time increased for external factors, as the 
breakdowns. The 220 remaining implants were divided into 5 
groups of 44 each one. 
Results: We observed a decrease in the time consumed to 
apply this treatment throughout the 8 years (116.1 minutes 
on average), with statistical significance (p<0.001). The 
average D90 was 109.9% with a significant difference among 
the five periods (p<0.001). Similarly, we found significant 
differences for V100 (average 94.1%), V150 (average 59.6%), 
V200 (average 34,1%) and RV100 (average 0.22%). We 
measured a consistent result into nomogram linear data 
adjustment for all PPB treatments (n=220), with a 0.8437 
value for correlation coefficient (R2).  
 
 
 
 
Conclusions: We observed a learning curve for several 
implantation parameters, which led to a meaningful 
suggestion in prostate coverage doses, decrease in rectal 
doses and diminution in the implantation time needed for 
PPB. 
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Purpose/Objective: To assess the 5-year outcomes of 
patients with intermediate-risk prostate cancer treated with 
hypofractionated external beam radiotherapy (EBRT) and 
high-dose-rate (HDR) brachytherapy boost combined with 
short course androgen deprivation therapy (ADT). 
Materials and Methods: From August 2003 to September 
2007, fifty-one patients with intermediate-risk prostate 
cancer were enrolled in a dose escalation phase II protocol 
(BRP-1 trial) at our institution. Treatment regimen was as 
followed: Six months of ADT, One HDR prostate 
brachytherapy Ir192 was performed under trans-rectal 
ultrasound guidance. Three fractions of 6.5Gy each for a 
total of 19.5Gy were delivered using inverse planning 
technique. Hypofractionated EBRT to 50Gy in 20 fractions 
was delivered to the prostate and proximal seminal vesicles 
and began one week after brachytherapy. Patients were 
assessed every week during treatments, one month post-
treatment and every three to six months thereafter. APS, 
testosterone and complete blood count were taken on each 
visit. The Phoenix biochemical failure (BF) definition was 
used. Gastrointestinal (GI), genitourinary (GU) and sexual 
toxicities were recorded according to the RTOG toxicity 
3rd ESTRO Forum 2015                                                                                                                                         S563 
 
scoring criteria. Patients also completed the Expanded 
Prostate Cancer Index Composite (EPIC) questionnaires for 
quality of life every 6 months. 
Results: Median follow-up was 80 months (range 4.9-132 
months). Median patient age was 68.5 years (range 51-83 
years). The majority of patients had T1c or T2 clinical stage, 
60.8% had a Gleason score of 7 and median PSA was 9.3 
ng/mL (range 3-24.4 ng/mL). Recurrence was observed in 
five patients which lead to a BF rate of 9.8%. The 5-year 
cancer specific survival (CSS) and overall survival (OS) were 
100% and 87.9%, respectively. The 11-year estimated CSS and 
OS were 85.3% and 67.8%, respectively. The Fisher's exact 
test showed that the only significant predictor BF was 
Gleason score of 8. Late toxicity included grade 2 
gastrointestinal (GI) toxicity in 2 (5.9%) patients and no grade 
3 GI toxicity; genitourinary toxicity grades 2 and 3 in 3 (9%) 
and 5 (14.7%) patients, respectively; as well as erectile 
function grades 2 and 3 in 27 (31%) patients. 
Conclusions: These long-term outcomes confirm that 
hypofractionated EBRT plus HDR brachytherapy boost 
provides good results in terms of treatment-related toxicity 
and biochemical control for intermediate to high risk 
prostate cancer. We believe these findings support the use of 
HDR brachytherapy as a valuable dose escalation modality for 
localized prostate cancer.  
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Purpose/Objective: To develop a model for PSA antigen 
values at one year among patients treated with 
intraoperative planning based I-125 prostate brachytherapy 
(IOPB). 
Materials and Methods: In this retrospective cohort study, 
407 patients who received treatment with low dose rate 
prostate brachytherapy for prostate adenocarcinoma and had 
at least one measured PSA value within the first year post 
treatment were divided into four groups: those with PSA 
values ≥ 3, those with PSA <3 and ≥2, those with PSA <2 and ≥ 
1 and those with 1 year PSA value <1 measured between 10.5 
and 14.5 months post implantation. Ordinal regression 
analysis was then performed between patient, tumor and 
treatment characteristics. 
Results: A total of 870 patients with low to low-tier 
intermediate risk prostate cancer were treated with IOPB 
between June 2003 and July 2014. 460 patients had PSA 
measurements within the first year post treatment. 53 of 
these received hormone therapy and were excluded from this 
analysis. This cohort had median age 63.3 years (range: 45-
81) and pre-treatment PSA of 5.82ng/mL (0.34-13.8). Almost 
all patients were Gleason 6 (74%) or Gleason 7 (26%). 310 
patients had T1c disease (71 had T2a and 9 had T2b). Median 
percentage of positive biopsy tissue was 5.0% (0.5-60), 
median time from biopsy to treatment was 5.5 months (0.33-
70.2). Median prostate volume was 33.89cc. Median source 
activity was .437mCi (0.343-0.481) and a median of 72 seeds 
(41-99) in 26 needles (19-77) were used. Median D90 was 
190.0Gy (137.5-202.0). One year PSA values were measured 
at a median of 12 months (10.5-14.5). Median PSA at this 
time was 0.77 (0.04-17.36).  32 patients (8%) had a PSA ≥3; 
35 (9%) had PSA <3, ≥2; 87 (21%) had PSA <2, ≥1 and most 
patients 254 (62%) had PSA <1. On ordinal modeling, PSA 
response was independent of gland volume, Gleason score, 
clinical stage, time from initial biopsy to implantation, seed 
activity and number of needles and seeds used. There was no 
relationship between PSA at one year and implant V90, V200 
or D90. Older patients had significantly lower 1 year PSA 
values; median ages 65.1 (46.5-81.0), 62.1 (50.4-79.5), 60.5 
(47.1-80.3) and 58.1 (45.1-74.2) years for each of the 1 year 
PSA groups respectively (p<0.001). Also, both implant V150 
and initial PSA values showed direct correlation with 
measured PSA values at 1 year (p<0.001 and p=0.004 
respectively).  
Conclusions: PSA response at 1 year post intraoperative plan 
based prostate brachytherapy is dependent on patient age, 
initial PSA and implant V150. These factors may be useful 
when counseling patients on expectations regarding PSA 
response post prostate brachytherapy. Although early 
prediction of low dose rate brachytherapy treatment failure 
remains elusive, initial prediction of treatment response may 
allow better determination of which patients will require 
closer follow-up post implantation. Our results are reassuring 
to patients that parameters other than failure may be 
responsible for PSA values >1 at 1 year. 
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